Minoxidil

Spezifikationen

38304-91-5CAS-Nummer

3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amineIUPAC-Name

C9H15N5OChemische Formel

209.25 g/molMolekulargewicht

minoxidil; 38304-91-5; Loniten; Rogaine; Minoximen; Theroxidil; Alopexil; Alostil; Tricoxidil; Lonolox; Regaine; Normoxidil; Prexidil; Minodyl; Pierminox; 2,6-Diamino-4-(piperidin-1-yl)pyrimidine 1-oxide; RiUP; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; Mintop; U-10858; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide; DTXSID9040685; U-10,858; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; NSC-757106; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; MLS000028566; CHEBI:6942; Minossidile [Italian]; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; MFCD00063409; 2,6-diamino-4-(piperidin-1-yl)pyrimidin-1-ium-1-olate; Minoxidilum [INN-Latin]; NCGC00015673-08; Minoxidilum; SMR000058963; CAS-38304-91-5; Apo-Gain; 6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; DTXCID7020685; Neoxidil; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,6-diamino-4-piperidylpyrimidin-1-ol; SMR000326812; Loniten (TN); Rogaine (TN); Riup (TN); SR-01000075331; SR-05000001479; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; Minoxidil CRS; Regaine For Men; Avacor and Mintop; Regaine For Women; Prestwick_521; TM-160; Men''''s Rogaine; Women''''s rogaine; Rogaine Extra Strength; Spectrum_000969; Tocris-0583; MINOXIDIL [INN]; MINOXIDIL [JAN]; MINOXIDIL [MI]; Minoxidil Extra Strength; MINOXIDIL [HSDB]; MINOXIDIL [USAN]; regid855572; Opera_ID_1150; Prestwick0_000020; Prestwick1_000020; Prestwick2_000020; Prestwick3_000020; Spectrum2_001053; Spectrum3_000509; Spectrum4_000063; Spectrum5_001299; Lopac-M-4145; MINOXIDIL [VANDF]; M1389; CHEMBL802; MINOXIDIL [MART.]; M 4145; MINOXIDIL [USP-RS]; MINOXIDIL [WHO-DD]; Minoxidil (JAN/USP/INN); CBiol_001798; Lopac0_000786; SCHEMBL29698; BSPBio_000059; BSPBio_001385; BSPBio_002037; KBioGR_000105; KBioGR_000585; KBioSS_000105; KBioSS_001449; MLS000859953; MLS001077294; DivK1c_000160; SPECTRUM1500415; Minoxidil - Bio-X trade mark; SPBio_001006; SPBio_001980; BPBio1_000065; CHEMBL609587; GTPL4254; Minoxidil, >=99% (TLC); orb1225141; SGCUT00112; MINOXIDIL [ORANGE BOOK]; CHEMBL1372483; MINOXIDIL [EP MONOGRAPH]; SCHEMBL29365549; BCBcMAP01_000193; BDBM81463; CHEBI:92128; HMS500H22; KBio1_000160; KBio2_000105; KBio2_001449; KBio2_002673; KBio2_004017; KBio2_005241; KBio2_006585; KBio3_000209; KBio3_000210; KBio3_001537; MINOXIDIL [USP MONOGRAPH]; NINDS_000160; ZFMITUMMTDLWHR-UHFFFAOYSA-N; Bio1_000084; Bio1_000573; Bio1_001062; Bio2_000105; Bio2_000585; DTXSID301372970; HMS1361F07; HMS1568C21; HMS1791F07; HMS1920P03; HMS1989F07; HMS2089L08; HMS2091F20; HMS2095C21; HMS2233E04; HMS2235N21; HMS3259P21; HMS3262M14; HMS3266O06; HMS3371E15; HMS3372M19; HMS3402F07; HMS3411G16; HMS3675G16; HMS3712C21; Pharmakon1600-01500415; 6-amino-2-imino-4-(piperidin-1-yl)-1,2-dihydropyrimidin-1-ol; CAS_4201; HY-B0112; NSC_4201; to_000070; VQB71866; Tox21_110193; Tox21_500786; BDBM50237593; CCG-40112; EBC-06508; HB1094; MFCD00072128; Minoxidil for system suitability CRS; MSK000473; NSC757106; s1383; SBB056986; AKOS015920078; AKOS016339636; Tox21_110193_1; AC-5271; CCG-220020; CS-1867; DB00350; FD26009; GS-3605; KS-5164; LP00786; NC00686; SDCCGSBI-0050764.P005; IDI1_000160; IDI1_033855; SMP1_000192; NCGC00015673-01; NCGC00015673-02; NCGC00015673-03; NCGC00015673-04; NCGC00015673-05; NCGC00015673-06; NCGC00015673-07; NCGC00015673-09; NCGC00015673-10; NCGC00015673-11; NCGC00015673-12; NCGC00015673-13; NCGC00015673-20; NCGC00018278-01; NCGC00018278-02; NCGC00018278-03; NCGC00018278-04; NCGC00024666-01; NCGC00024666-02; NCGC00024666-03; NCGC00024666-04; NCGC00024666-05; NCGC00024666-06; NCGC00024666-07; NCGC00024666-08; NCGC00179672-01; NCGC00261471-01; BD164673; PD003089; SY075383; SBI-0050764.P004; 2,6-Diamino-4-piperidinopyrimidine 1-Oxide; 5965120SH1; AB00513797; EU-0100786; M3453; NS00014997; ST50993884; D00418; EN300-121204; H10337; O10620; U10858; 6-(1-Piperidinyl)-2,4-pyrimidinediamine3-oxide; AB00052047-08; AB00052047_09; AB00052047_10; AB00513797-02; Q424165; SR-01000075331-1; SR-01000075331-3; SR-01000075331-5; SR-05000001479-1; SR-05000001479-2; 2,4-DIAMINO-6-PIPERIDINOPYRIMIDINE 3-OXIDE.; BRD-K06902185-001-05-2; BRD-K06902185-001-10-2; BRD-K06902185-001-16-9; BRD-K06902185-001-17-7; BRD-K06902185-003-01-7; BRD-K14888893-001-02-3; BRD-K14888893-001-14-8; Minoxidil, British Pharmacopoeia (BP) Reference Standard; Z1541638524; Minoxidil, European Pharmacopoeia (EP) Reference Standard; 1-Oxo-4-(piperidin-1-yl)-1lambda~5~-pyrimidine-2,6-diamine; 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidino-pyrimidine; Minoxidil, United States Pharmacopeia (USP) Reference Standard; Minoxidil for system suitability, European Pharmacopoeia (EP) Reference Standard; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 6-(1-Piperidinyl)pyrimidine-2,4-diamine 3-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxideSynonyme